Prime Medicine Inc PRME
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRME is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.51
- Day Range
- $4.38–4.91
- 52-Week Range
- $4.34–17.20
- Bid/Ask
- $4.80 / $4.92
- Market Cap
- $573.31 Mil
- Volume/Avg
- 1.4 Mil / 732,542
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 234
- Website
- https://www.primemedicine.com
Comparables
Valuation
|
Metric
|
PRME
|
BEAM
|
JANX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.36 | 2.00 | 6.54 |
Price/Sales | — | 4.92 | 265.14 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PRME
|
BEAM
|
JANX
|
|---|---|---|---|
Quick Ratio | 2.16 | 5.79 | 26.40 |
Current Ratio | 2.53 | 5.89 | 26.80 |
Interest Coverage | — | — | — |
Quick Ratio
PRME
BEAM
JANX
Profitability
|
Metric
|
PRME
|
BEAM
|
JANX
|
|---|---|---|---|
Return on Assets (Normalized) | −60.51% | −3.95% | −10.49% |
Return on Equity (Normalized) | −72.42% | −6.58% | −11.78% |
Return on Invested Capital (Normalized) | −66.12% | −9.14% | −15.13% |
Return on Assets
PRME
BEAM
JANX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wlpgwfrkt | Jprr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wwxsrtfb | Pfyxbf | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gwfpvdshp | Qgmpjcr | $98.8 Bil | |
MRNA
| Moderna Inc | Wkhspym | Ffjz | $38.8 Bil | |
ARGX
| argenx SE ADR | Nyksxqhqj | Smkg | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Ywbpvyws | Qlpc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bwskcqzn | Txsrdwc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lyjkdblm | Pkdlwtn | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cnzcrpwzs | Zjcvvrp | $12.4 Bil | |
INCY
| Incyte Corp | Mxmqwxyxv | Tfvvrw | $11.9 Bil |